Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy

Blood

Volumn 121, Issue 24, 2013, Pages 4821-4831

  Boyerinas, Benjamin ^a   Zafrir, Maya ^a   Yesilkanal, Ali E ^a   Price, Trevor T ^a   Hyjek, Elizabeth M ^b   Sipkins, Dorothy A ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 4 BETA 1 INTEGRIN; ALPHA 5 BETA 1 INTEGRIN; ALPHA 9 BETA 1 INTEGRIN; CYTARABINE; HERMES ANTIGEN; INTEGRIN; KI 67 ANTIGEN; OSTEOPONTIN; THROMBIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; NEUTRALIZING ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL MATURATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRAVITAL MICROSCOPY; LEUKEMIA CELL; LEUKEMOGENESIS; LEUKOCYTE COUNT; LYMPHOBLAST; MACROPHAGE; MICROSCOPY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TRABECULAR BONE; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ADULT; ANIMAL; BLAST CELL CRISIS; CANCER TRANSPLANTATION; CELL ADHESION; CHILD; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; XENOGRAFT;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIMETABOLITES, ANTINEOPLASTIC; BLAST CRISIS; BONE MARROW; CELL ADHESION; CHILD; CHILD, PRESCHOOL; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; OSTEOBLASTS; OSTEOPONTIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

MLCS; MLOWN;

EID: 84881288585     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-475483     Document Type: Article

References (39)

1. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389-405.
2. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
3. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435(7044):969-973. (Pubitemid 40896324)
4. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137(4):288-296. (Pubitemid 46650259)
5. Lévesque JP, Helwani FM, Winkler IG. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukemia. 2010;24(12):1979-1992.
6. Porter RL, Calvi LM. Communications between bone cells and hematopoietic stem cells. Arch Biochem Biophys. 2008;473(2):193-200.
7. Wilson A, Oser GM, Jaworski M, et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci. 2007;1106:64-75. (Pubitemid 47443057)
8. Haylock DN, Williams B, Johnston HM, et al. Hemopoietic stem cells with higher hemopoietic potential reside at the bone marrow endosteum. Stem Cells. 2007;25(4):1062-1069. (Pubitemid 46572605)
9. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Lévesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375-385.
10. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977-988. (Pubitemid 44894948)
11. Arai F, Suda T. Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann N Y Acad Sci. 2007;1106:41-53. (Pubitemid 47443041)
12. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-161. (Pubitemid 38962572)
13. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. (Pubitemid 350215333)
14. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
15. Standal T, Hjorth-Hansen H, Rasmussen T, et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica. 2004;89(2):174-182. (Pubitemid 38796491)
16. Caers J, Günthert U, De Raeve H, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol. 2006;132(4):469-477. (Pubitemid 43381618)
17. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16(2):79-87. (Pubitemid 43247403)
18. Haylock DN, Nilsson SK. Osteopontin: a bridge between bone and blood. Br J Haematol. 2006;134(5):467-474. (Pubitemid 44141712)
19. Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 1996;271(45):28485-28491. (Pubitemid 26374670)
20. Grassinger J, Haylock DN, Storan MJ, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009;114(1):49-59.
21. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232-1239. (Pubitemid 41129584)
22. Mi Z, Guo H, Kuo PC. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes. 2009;2:119.
23. Lee J-L, Wang M-J, Sudhir P-R, Chen G-D, Chi C-W, Chen J-Y. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007;67(5):2089-2097. (Pubitemid 46424227)
24. Cui R, Takahashi F, Ohashi R, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 2007;57(3):302-310. (Pubitemid 47285419)
25. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegård D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis. 2003;20(5):437-444. (Pubitemid 37108430)
26. Lee CY, Tien HF, Hou HA, Chou WC, Lin LI. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol. 2008;141(5):736-739.
27. Powell JA, Thomas D, Barry EF, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 2009;114(23):4859-4870.
28. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-1865.
29. Tario JD Jr, Muirhead KA, Pan D, Munson ME, Wallace PK. Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods Mol Biol. 2011;699:119-164.
30. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood. 1995;85(9):2537-2545.
31. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154(1):180-191.
32. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther. 2009;17(1):153-161.
33. Zhu B, Suzuki K, Goldberg HA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol. 2004;198(1):155-167. (Pubitemid 38120976)
34. Marcondes MC, Poling M, Watry DD, Hall D, Fox HS. In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression. Cell Immunol. 2008;254(1):56-62.
35. Borowitz MJ, Devidas M, Hunger SP, et al Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
36. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731-1738. (Pubitemid 28534955)
37. Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201(11):1781-1791. (Pubitemid 41002897)
38. Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci. 2001;114(Pt 14):2553-2560. (Pubitemid 32734404)
39. Hsieh Y-T, Park E, Jiang E, et al. Adjuvant CD49d blockade eradicates chemoresistant ALL. In: Proceedings from the American Society of Hematology; December 7, 2010; Orlando, FL. Abstract 869.